苹果酸脱氢酶2在肿瘤中的作用机制

国际肿瘤学杂志››2019,Vol. 46››Issue (3): 178-180.doi:10.3760/cma.j.issn.1673-422X.2019.03.010

苹果酸脱氢酶2在肿瘤中的作用机制

吴颖1付白雪1戴璐2黄俊2滕一镔2李琳琳2章静雯2黄玉红1

1大连医科大学基础医学院病理教研室116044； 2大连医科大学临床医学院116044

出版日期:2019-03-08发布日期:2019-05-17
通讯作者:黄玉红 E-mail:huangyh_1020@163.com
基金资助:

辽宁省教育厅betway必威亚洲项目（L2013356）；教育部留学回国人员科研启动基金（〔2010〕1561）

Functional mechanism of malate dehydrogenase 2 in tumors

Wu Ying1, Fu Baixue1, Dai Lu2, Huang Jun2, Teng Yibin2, Li Linlin2, Zhang Jingwen2, Huang Yuhong1

1Department of Pathology, Basic Medical College of Dalian Medical University, Dalian 116044, China; 2Clinical Medical College of Dalian Medical University, Dalian 116044, China

Online:2019-03-08Published:2019-05-17
Contact:Huang Yuhong E-mail:huangyh_1020@163.com
Supported by:

Liaoning Provincial Department of Education Scientific Research General Project (L2013356); Research Fund for the Return of Students from the Ministry of Education (〔2010〕1561)

摘要/Abstract

摘要：苹果酸脱氢酶2（MDH2）在肿瘤中的作用存在双面性，在一些肿瘤中具有促癌作用，而在另一些肿瘤中具有抑制作用。MDH2的功能与能量代谢、肿瘤耐药性及其伪缺氧相互联系。MDH2在肿瘤的发生、发展、侵袭和转移中起重要作用，深入了解MDH2在肿瘤中的作用机制，可为临床提供新的肿瘤干预分子靶点。

吴颖，付白雪，戴璐，黄俊，滕一镔，李琳琳，章静雯，黄玉红. 苹果酸脱氢酶2在肿瘤中的作用机制[J]. 国际肿瘤学杂志, 2019, 46(3): 178-180.

Wu Ying1, Fu Baixue, Dai Lu, Huang Jun, Teng Yibin, Li Linlin, Zhang Jingwen, Huang Yuhong. Functional mechanism of malate dehydrogenase 2 in tumors[J]. Journal of International Oncology, 2019, 46(3): 178-180.

参考文献

［1］ Liu R, Wang H, Liu J, et al. Uncovering the embryonic developmentrelated proteome and metabolome signatures in breast muscle and intramuscular fat of fastand slowgrowing chickens［J］. BMC Genomics, 2017, 18(1): 816. DOI: 10.1186/s1286401741503. ［2］ AitElMkadem S, DayemQuere M, Gusic M, et al. Mutations in MDH2, encoding a Krebs cycle enzyme, cause earlyonset severe encephalopathy［J］. Am J Hum Genet, 2017, 100(1): 151159. DOI: 10.1016/j.ajhg.2016.11.014. ［3］ Oldham WM, Clish CB, Yang Y, et al. Hypoxiamediated increases in L2hydroxyglutarate coordinate the metabolic response to reductive stress［J］. Cell Metab, 2015, 22(2): 291303. DOI: 10.1016/j.cmet.2015.06.021. ［4］ Lo YW, Lin ST, Chang SJ, et al. Mitochondrial proteomics with siRNA knockdown to reveal ACAT1 and MDH2 in the development of doxorubicinresistant uterine cancer［J］. J Cell Mol Med, 2015, 19(4): 744759. DOI: 10.1111/jcmm.12388. ［5］ Kim BS, Lee K, Jung HJ, et al. HIF1α suppressing small molecule, LW6, inhibits cancer cell growth by binding to calcineurin b homologous protein 1［J］. Biochem Biophys Res Commun, 2015, 458(1): 1420. DOI: 10.1016/j.bbrc.2015.01.031. ［6］ Taniguchi S, Shimatani Y, Fujimori M, et al. Tumortargeting therapy using geneengineered anaerobicnonpathogenic bifidobacterium longum［J］. Methods Mol Biol, 2016, 1409: 4960. DOI: 10.1007/9781493935154_5. ［7］ Zhuang Y, Xiang J, Bao W, et al. MDH2 stimulated by estrogenGPR30 pathway downregulated PTEN expression promoting the proliferation and invasion of cells in endometrial cancer［J］. Transl Oncol, 2017, 10(2): 203210. DOI: 10.1016/j.tranon.2017.01.009. ［8］ Ban HS, Xu X, Jang K, et al. A novel malate dehydrogenase 2 inhibitor suppresses hypoxiainducible factor1 by regulating mitochondrial respiration［J］. PLoS One, 2016, 11(9): e0162568. DOI: 10.1371/journal.pone.0162568. ［9］ Wei J, Yang Y, Lu M, et al. Recent advances in the discovery of HIF1αp300/CBP inhibitors as anticancer agents［J］. Mini Rev Med Chem, 2018, 18(4): 296309. DOI: 10.2174/1389557516666160630124938. ［10］ Lima Queiroz A, Zhang B, Comstock DE, et al. miR1265p targets malate dehydrogenase 1 in nonsmall cell lung carcinomas［J］. Biochem Biophys Res Commun, 2018, 499(2): 314320. DOI: 10.1016/j.bbrc.2018.03.154. ［11］ Latonen L, Afyouniab E, Jylh A, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression［J］. Nat Commun, 2018, 9(1): 1176. DOI: 10.1038/s41467018035736. ［12］ Cascón A, CominoMéndez I, CurrásFreixes M, et al. Wholeexome sequencing identifies MDH2 as a new familial paragangliomagene［J］. J Natl Cancer Inst, 2015, 107(5): pii: djv053. DOI: 10.1093/jnci/djv053. ［13］ Liu Y, Asnani A, Zou L, et al. Visnagin protects against doxorubicininduced cardiomyopathy through modulation of mitochondrial malate dehydrogenase［J］. Sci Transl Med, 2014, 6(266): 266170. DOI: 10.1126/scitranslmed.3010189. ［14］ Beezhold K, Byersdorfer CA. Targeting immunometabolism to improve anticancer therapies［J］. Cancer Lett, 2018, 414: 127135. DOI: 10.1016/j.canlet.2017.11.005. ［15］ Ylip A, Kivinummi K, Kohvakka A, et al. Transcriptome sequencing reveals PCAT5 as a novel ERGregulated long noncoding RNA in prostate cancer［J］. Cancer Res, 2015, 75(19): 40264031. DOI: 10.1158/00085472.CAN150217. ［16］ Kratochvilova M, Raudenska M, Heger Z, et al. Amino acid profiling of zinc resistant prostate cancer cell lines: associations with cancer progression［J］. Prostate, 2017, 77(6): 604616. DOI: 10.1002/pros.23304. ［17］ Shen H, Hau E, Joshi S, et al. Sensitization of glioblastoma cells to irradiation by modulating the glucose metabolism［J］. Mol Cancer Ther, 2015, 14(8): 17941804. DOI: 10.1158/15357163.MCT150247. ［18］ Gentric G, Kieffer Y, Mieulet V, et al. PMLregulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers［J］. Cell Metab, 2019, 29(1): 156173.e10. DOI: 10.1016/j.cmet.2018.09.002. ［19］ Zhang B, Tornmalm J, Widengren J, et al. Characterization of the role of the malate dehydrogenases to lung tumor cell survival［J］. J Cancer, 2017, 8(11): 20882096. DOI: 10.7150/jca.19373. ［20］ Xi L. Visnagin—a new protectant against doxorubicin cardiotoxicity? Inhibition of mitochondrial malate dehydrogenase 2 (MDH2) and beyond［J］. Ann Transl Med, 2016, 4(4): 65. DOI: 10.3978/j.issn.23055839.2015.10.43. ［21］ Ippolito L, Marini A, Cavallini L, et al. Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells［J］. Oncotarget, 2016, 7(38): 6189061904. DOI: 10.18632/oncotarget.11301. ［22］ Ciccarone F, Vegliante R, Di Leo L, et al. The TCA cycle as a bridge between oncometabolism and DNA transactions in cancer［J］. Semin Cancer Biol, 2017, 47: 5056. DOI: 10.1016/j.semcancer.2017.06.008. ［23］ Jochmanová I, Zhuang Z, Pacak K. Pheochromocytoma: gasping for air［J］. Horm Cancer, 2015, 6(56): 191205. DOI: 10.1007/s1267201502314. ［24］ Chen C, Zhang LG, Liu J, et al. Bioinformatics analysis of differentially expressed proteins in prostate cancer based on proteomics data［J］. Onco Targets Ther, 2016, 9: 15451557. DOI: 10.2147/OTT.S98807.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.